Bispecific T cell engager eliminates senescent cells in mice and nonhuman primates
Monitored by serum transaminase levels, low doses of the drug alleviated age-related pathologies without causing the hepatotoxicity seen at higher doses.
Aging cell · Deng J et al. · Paper published 29 Sep 2026
In aged mice and non-human primates, a newly designed bispecific T-cell engager safely eliminated senescent cells and improved age-related pathologies. While CAR-T cells targeting uPAR cause unpredictable toxicities, bispecific T-cell engagers offer better dose control. Researchers developed GFD-CD3, an engager using the natural uPA ligand domain to target uPAR-positive senescent cells. In dose-finding tests, high doses caused hepatotoxicity via T cell-mediated damage to hepatic endothelial cells. Guiding treatment with serum transaminase monitoring allowed researchers to identify a safe low dose. At this lower dose, GFD-CD3 cleared senescent cells and alleviated age-related pathologies in both species without inducing adverse effects.
Why it matters
Clearing senescent cells can alleviate age-related dysfunctions, but immunotherapies often trigger severe off-target toxicities. Demonstrating that titratable T-cell engagers can safely remove senescent cells in non-human primates offers a potential path toward clinical senolytic immunotherapies.
Caveats
The findings remain restricted to animal models, and clinical translation requires confirming the safety and efficacy of transaminase-guided dosing in humans.
Written from the paper’s abstract, and every claim checked against it before publishing. Read the paper for the full methods and data.
The paper
uPAR-Targeting T Cell Engager Exerts Senolytic Effects in Mice and Non-Human Primates With Serum Aminotransferase Activity as a Safety Monitor
Deng J, Zeng X, Guo J et al.
Aging cell · 29 Sep 2026 · Peer-reviewed
- Relevance
- Core geroscience
- News value
- Important
- Evidence
- Animals
- Status
- Peer-reviewed
More on Cellular senescence
See allDasatinib and quercetin reduce liver fibrosis in a phase-2 MASH trial
The senolytic combination improved liver fibrosis without disease worsening in nearly half of treated participants while lowering cellular senescence markers.
Nature metabolism · Koning M et al.
A distinct p21-driven macrophage senotype accumulates during aging and liver disease
Researchers identified a p53-p21-Cyclin D2 axis that governs senescent macrophages in mice and human liver cirrhosis and can be cleared with senolytics.
bioRxiv · Torres G et al.
DNA methylation proxies of senescence markers track human disease and mortality
The new blood-based tools estimate senescence gene activity to predict incident diseases, all-cause mortality, and clinical treatment responses.
medRxiv · Simpson DJ et al.
A deep learning score for cellular senescence predicts human mortality and disease risk
The proteomic biomarker tracked chronic illness risk in the UK Biobank and shifted following an 18-month multimodal exercise intervention.
Aging cell · Zhao S et al.
Lactate receptor activation reduces cellular senescence and protects vascular health in mice
Loss of the lactate receptor GPR81 drives arterial senescence and lipid accumulation, while pharmacological stimulation restores vascular homeostasis in progeroid mice.
bioRxiv · Wu Y et al.